Clinical trial NCT03787498: A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Official title: A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Relapsed Acute Myeloid Leukemia (AML)
Refractory Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome (MDS)
Keywords: PLX2853
Acute Myeloid Leukemia
AML
Myelodysplastic Syndrome
MDS
Hematologic Malignancy
Blood Cancer
Lead sponsor: Opna Bio LLC
Sponsor class: INDUSTRY
First posted: 2018-12-26
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome


Eligibility criteria: Inclusion Criteria:

1. Confirmed diagnosis of one of the following myeloid malignancies, based on the 2016 revision of the World Health Organization classification:

   A. Relapsed or refractory AML.

   I. Subjects must have received no more than 3 prior induction therapies and have no standard therapeutic option that is expected to result in a clinical benefit.

   B. Relapsed or refractory MDS.

   I. Subjects must have high-risk disease (intermediate or greater disease according to the revised International Prognostic Scoring System \[IPSS-R\]).

   II. Subjects must have received no more than 3 prior therapies, 1 of which must have included a hypomethylating agent such as azacytidine or decitabine.

   III. Subjects must have no standard therapeutic option that is expected to result in a clinical benefit.
2. Age ≥18 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
4. Life expectancy of ≥3 months in the judgment of the investigator.
5. Adequate renal, hepatic, and coagulation parameters:

   A. Measured or calculated (Cockcroft-Gault formula) creatinine clearance (CrCl) ≥60 mL/min.

   B. Total bilirubin ≤1.5 × ULN unless due to Gilbert's syndrome.

   C. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.

   D. Prothrombin time or international normalized ratio ≤1.5 × ULN.

   E. Activated partial thromboplastin time ≤1.5 × ULN.
6. Women of child-bearing potential must have a negative pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test to 90 days after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraception in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
7. Fertile men must agree to use an effective method of birth control during the study and for 90 days after the last dose of study drug.
8. Resolution (to ≤Grade 1 or baseline) of all significant toxicity associated with prior cancer therapy prior to study drug initiation. (Grade 2 alopecia or residual Grade 2 peripheral neuropathy is allowed.)
9. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements.

Exclusion Criteria:

1. Prior treatment with a bromodomain inhibitor.
2. Any one of the following therapies:

   A. Stem cell transplantation within 90 days of study drug initiation;

   B. Active immunosuppressive therapy for graft-versus-host disease (GVHD);

   C. GVHD prophylaxis within 2 weeks of study drug initiation.
3. Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2.
4. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia.
5. Active symptomatic central nervous system involvement of AML. (Individuals who have had leptomeningeal disease that was effectively treated are eligible.)
6. A diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia in blast crisis.
7. Known or suspected allergy to the study drug or any agent given in association with this trial.
8. Women who are either pregnant or breast feeding.
9. Clinically significant cardiac disease.
10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption.
11. Individuals who are known to be infected with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) or are known carriers of HBV or HCV. Individuals who are positive for HCV antibody must be negative for HCV RNA by polymerase chain reaction (PCR) to be eligible. Individuals with occult or prior HBV infection (defined as being seropositive for total hepatitis B core antibody and seronegative for hepatitis B surface antigen) may be included if HBV DNA is undetectable. These individuals must be willing to undergo additional testing per local standard of care.
12. Active second malignancy with the exception of any of the following:

    * Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer;
    * Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years;
    * Low-risk prostate cancer with Gleason score \<7 and prostate-specific antigen \<10 ng/mL;
    * Any other cancer from which the patient has been disease-free for ≥3 years.
13. Major surgery or significant injury within the 14-day period prior to study drug initiation.
14. Anti-cancer therapy in the period immediately preceding study drug initiation.
15. Any other medical, psychological, familial, sociologic, or geographic condition that, in the judgement of the investigator, would potentially hamper compliance with the study protocol or interfere with the study endpoints or the subject's ability to participate in the study.
16. Participation in any other therapeutic clinical study. (Participation in observational or registry trials is allowed.)
17. Individuals who are on active anticoagulation therapy (e.g., warfarin, factor Xa inhibitors, thrombin inhibitors, heparin).

Primary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
timeFrame: First dose of study drug through at least 30 days after end of treatment
measure: Area under the concentration-time curve (AUC) of PLX2853
timeFrame: From first dose of PLX2853 up to 30 days after end of treatment
measure: Maximum observed concentration (Cmax) of PLX2853
timeFrame: From first dose of PLX2853 up to 30 days after end of treatment
measure: Time to peak concentration (Tmax) of PLX2853
timeFrame: From first dose of PLX2853 up to 30 days after end of treatment
measure: Half life (t1/2) of PLX2853
timeFrame: From first dose of PLX2853 up to 30 days after end of treatment
measure: Terminal elimination rate constant (Kel)
timeFrame: From first dose of PLX2853 up to 30 days after end of treatment
measure: Number of participants who experience dose limiting toxicity as defined in the protocol
timeFrame: up to 18 months
Secondary outcomes:
measure: Overall complete remission (OCR) rate
timeFrame: From the first dose of study drug until the date of documented best response to treatment, assessed up to 18 months
measure: Overall response rate (ORR)
timeFrame: From the first dose of study drug until the date of documented response to treatment, assessed up to 18 months
measure: Duration of response (DOR)
timeFrame: DOR defined as the time from the initial objective response to disease progression or death, whichever occurs first, assessed up to 18 months
measure: Event-free survival (EFS)
timeFrame: EFS time is defined as the time from the first dose of PLX2853 to treatment failure, relapse after initial response or death from any cause, assessed up to 18 months.
measure: Progression-free survival (PFS)
timeFrame: PFS time is defined as the time from the first dose of PLX2853 to disease progression or death, whichever occurs first, assessed up to 18 months.
measure: Overall survival (OS)
timeFrame: From the first dose of study drug until the date of death from any cause, assessed up to 18 months.
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Northside Hospital
state: Georgia
city: Baltimore
country: United States
facility: Sidney Kimmel Comprehensive Cancer At Johns Hopkins
state: Maryland
city: New York
country: United States
facility: NewYork-Presbyterian / Weill Cornell Medical Center
state: New York
city: Columbus
country: United States
facility: Ohio State University Medical Center
state: Ohio
city: Portland
country: United States
facility: Oregon Health and Sciences University
state: Oregon
city: Houston
country: United States
facility: University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
References: